key: cord-0969259-ixpvy08k
authors: Kumar, Prabhakaran; Ratia, Kiira M; Richner, Justin M; Thatcher, Gregory R J; Kadam, Rashmi; Smieszek, Sandra P; Przychodzen, Bartlomiej P; Koprivica, Vuk; Birznieks, Gunther; Polymeropoulos, Mihael H; Prabhakar, Bellur S
title: Dual Inhibition of Cathepsin L and 3CL-Pro by GC-376 Constrains SARS Cov2 Infection Including Omicron Variant
date: 2022-02-10
journal: bioRxiv
DOI: 10.1101/2022.02.09.479835
sha: 3f9ca6a553c5cd8ec1493e9218b48b2955fa5e02
doc_id: 969259
cord_uid: ixpvy08k

Recurrent waves of SARS CoV2 infections remain a major global health concern. Emergence of highly infectious variants with reduced sensitivity to neutralization by vaccines and monoclonal antibodies (mAb) necessitates a deeper understanding of factors involved in SARS CoV2 infections and identification of drug candidates to halt infection. Here, we determined the primacy of endosomal protease cathepsin-L in mediating SARS CoV2 entry and screened a library of well-annotated bioactive compounds for potent cathepsin-L inhibitory activity. Whilst the potent cathepsin-L inhibitors were capable of inhibiting SARS CoV2 entry and cytopathic effect (CPE) in less susceptible cell lines such as human ACE2 expressing 293T cells, these drugs failed to inhibit SARS CoV2 in highly susceptible cell lines such as human TMPRSS2 or human-ACE2-TMPRSS2 overexpressing Vero E6 cells. Only drugs with dual inhibitory effect on both host cathepsin-L and virus 3CL-Protease enzymes such as Z-FA-FMK and GC-376 were capable of inhibiting prototypic (USA-WA1/2020, Lineage A) SARS CoV2 induced CPE in highly susceptible cell lines. Moreover, these drugs inhibited delta (Lineage-B.1.617.2) and omicron (Lineage-B.1.1.529) infection with equal potency showing that the newer mutations harbored in these variants did not affect the mechanism of action of these drugs such as cathepsin-L or 3CL-Pro inhibition. Moreover, our early evidence that 3CL-Pro inhibition can effectively inhibit omicron-induced CPE in highly susceptible cell lines suggests that the recently FDA-approved oral drug, a 3CL-Pro inhibitor which is a combination of nirmatrelvir/ritonavir (Paxlovid) could be effective against omicron variant which shows reduced sensitivity to vaccines and mAb. Importance We report that cathepsin-L and 3CL-Pro as major targets for designing antivirals against SARS CoV2. Dual inhibition of cathepsin-L and 3CL-Pro by GC-376 renders it effective in inhibiting SARS CoV2-induced cytopathic effect in highly susceptible cell lines. Moreover, this candidate drug is equally effective against prototypic SARS CoV2 lineage A and emerging variants such as delta and omicron which show reduced sensitivity to vaccines and monoclonal antibodies. Given the recent wave of SARS CoV2 omicron variant infection around the world, and 3CL-Pro inhibitor nirmatrelvir is one of the components of the FDA-approved Paxlovid, our findings are timely, important and should be of broad interest.

Recurrent waves of SARS CoV2 infections remain a major global health concern. Emergence of highly 26

infectious variants with reduced sensitivity to neutralization by vaccines and monoclonal antibodies (mAb) 27

necessitates a deeper understanding of factors involved in SARS CoV2 infections and identification of drug 28

candidates to halt infection. Here, we determined the primacy of endosomal protease cathepsin-L in mediating 29 SARS CoV2 entry and screened a library of well-annotated bioactive compounds for potent cathepsin-L 30 inhibitory activity. Whilst the potent cathepsin-L inhibitors were capable of inhibiting SARS CoV2 entry and 31

cytopathic effect (CPE) in less susceptible cell lines such as human ACE2 expressing 293T cells, these drugs 32 failed to inhibit SARS CoV2 in highly susceptible cell lines such as human TMPRSS2 or human-ACE2-33

TMPRSS2 overexpressing Vero E6 cells. Only drugs with dual inhibitory effect on both host cathepsin-L and 34

virus 3CL-Protease enzymes such as Z-FA-FMK and GC-376 were capable of inhibiting prototypic (USA-35 WA1/2020, Lineage A) SARS CoV2 induced CPE in highly susceptible cell lines. Moreover, these drugs 36

inhibited delta (Lineage-B.1.617.2) and omicron (Lineage-B.1.1.529) infection with equal potency showing that 37 the newer mutations harbored in these variants did not affect the mechanism of action of these drugs such as 38

cathepsin-L or 3CL-Pro inhibition. Moreover, our early evidence that 3CL-Pro inhibition can effectively inhibit 39 omicron-induced CPE in highly susceptible cell lines suggests that the recently FDA-approved oral drug, a 40 3CL-Pro inhibitor which is a combination of nirmatrelvir/ritonavir (Paxlovid) could be effective against omicron 41 variant which shows reduced sensitivity to vaccines and mAb. We report that cathepsin-L and 3CL-Pro as major targets for designing antivirals against SARS CoV2. Dual COVID19, originating in the Hubei province of China, is one of the most devastating pandemics the world has 71 ever witnessed (1). The repeated waves of COVID19 have caused more than 370 million infections and 72

accounted for 5.65 million deaths so far. While vaccination is proving to be the most effective weapon to fight 73 this pandemic, scaling up the production and distribution to meet the global need is extremely challenging. 74

Poor vaccination rates in third world countries can result in highly infectious forms of the variants such as delta 75

and omicron variants which might necessitate administration of booster doses of vaccine (2). On the other 76

hand, vaccine hesitancy could facilitate the spread of these newer variants despite the significant progress in 77

vaccinations. 78

A major concern associated with COVID19 is the emergence of mutant strains with higher transmissibility and 79

improved immune evasion mechanisms. For instance, the delta variant (B.1.617.2) was found to have ~2-fold 80

higher transmissibility than the prototypic lineage-A strain. The delta variant was shown to encompass 9 81 mutations within the spike protein which is targeted by many of the available vaccine candidates (3) and was 82

found to be 2.9 times less susceptible to neutralization by convalescent serum from recovered COVID19 83 patients (infected with lineage A) and sera from vaccinated individuals compared to the lineage A 84 USA/WA1/2020 strain (3). Similarly, increased immune evasion and reduced sensitivity to neutralization by the 85 sera from vaccinated individuals and monoclonal antibodies (mAb) have also been reported with the omicron 86 variant which has 30 mutations in the spike region (4, 5). The reduced neutralizing activity can be correlated 87

with the mutations harbored within the spike protein. All combinations of the FDA-approved mAbs such as 88 tixagevimab plus cilgavimab, imdevimab plus casirivimab, and etesevimab plus bamlanivimab, which 89 neutralized the early strain and the alpha and delta variants were found to be less effective in neutralizing the 90 omicron variant in at least in vitro neutralization assays (6). 91 SARS-nCoV-2 is a member of the Coronaviridae family and is an enveloped single-stranded RNA beta 92

coronavirus. The RNA genome of SARS CoV2 encodes 4 structural proteins namely, spike (S), membrane 93 (M), envelope (E), and nucleocapsid (N) proteins, and 16 nonstructural proteins (NSPs). The proteolytic 94 processing is carried out by two virus proteases namely, Papain -Like Protease (PL-Pro) and 3C-Like protease 95 (3CL-Pro alias M-Pro) which process NSP1-4 and NSP5-16 respectively (7). RNA-dependent RNA polymerase 96

(RdRp) of SARS Cov2 comprises of a catalytic subunit (nsp12) and two auxiliary subunits, (nsp8 and nsp7) 97

which regulate the replication and the transcription of its genes (8). Conventional antiviral drugs target specific 98 events of the virus life cycle such as viral attachment, fusion, replication, and protein synthesis. As of now, 99

FDA has granted authorization for three antiviral drugs namely remdesivir, molnupiravir, and 100 nirmatrelvir/ritonavir. Among these, remdesivir and molnupiravir are inhibitors of RNA-dependent RNA 101 polymerase (RdRp), and nirmatrelvir targets SARS CoV2 main protease (3CL-Protease) (9) (10). Apart from 102 the mutations located within the spike protein, Omicron variant has the second highest number of non-103 synonymous mutations in the RdRp. Additionally, mutations were also observed in the 3CL-protease encoding 104 regions (6, 11) which raise concerns about the clinical efficacy of these antiviral drugs. 105

Human ACE2 has been characterized as the most predominant receptor for SARS CoV2 (12, 13). The cell 106 entry mechanisms of enveloped viruses such as coronaviruses require the attachment of the viral spike (S) 107 structural glycoprotein to the host receptor and fusion with the host cell membrane which requires proteolysis 108 and acidification in endosomes (14). Upon binding to ACE2 receptor, SARS CoV2 exploits host proteases such 109 as transmembrane serine protease 2 (TMPRSS2) (13) and lysosomal cysteine proteases such as cathepsins 110

for the cleavage of the spike protein into S1/S2 subunits followed by fusion of S2 subunit to the host cells (12, 111 15). Intriguingly, SARS CoV2 spike protein contains an additional furin cleavage site, which is absent in SARS 112

CoV1(16) but present in MERS CoV (17), to exploit an additional host factor enhancing its infectivity. 113

Contradicting reports suggest varying degrees of importance of these host proteolytic enzymes in regulating 114 SARS CoV2 entry. Earlier, we have shown that small molecules that can prevent cathepsin L cleavage of viral 115 glycoproteins derived from SARS-CoV and Ebola, Hendra, and Nipah viruses could effectively inhibit their 116 entry into the host cells (18). 117

In this present study, we investigated the relative importance of TMPRSS2 and cathepsin L in mediating SARS 118

CoV2 entry and determined that cathepsin L is more critical in mediating SARS CoV2 entry. Further, we 119 screened a commercially available bioactive compound library for cathepsin L inhibitory activity and evaluated 120 the ability of these inhibitors to prevent the entry of pseudotyped SARS CoV2 particles as well as to inhibit 121

infectious SARS CoV2 induced cytopathic effect (CPE) in various cell lines. Our screening identified two known 122

protease inhibitors with pronounced cathepsin L inhibitor activity, namely Z-FA-FMK and GC-376, which 123 effectively inhibited virus entry and CPE at sub-micro-molar doses in 293T cells overexpressing human ACE2. 124

Both these compounds inhibited delta and omicron variants-induced CPE with the same efficacy as they 125

inhibited prototypic USA-WA1/2020 strain. More importantly, GC-376 which is a potent inhibitor of 3CL-Pro 126

inhibited SARS CoV2 induced CPE in highly susceptible Vero cells overexpressing human ACE2 and 127

TMPRSS2 indicating its higher potency. The cathepsin-L primary assay measures protease activity with a peptide substrate derived from the SARS-156

CoV-2 Spike protein. The FRET-based peptide, (TAMRA)-IIAYT/MSLGAK-(FAM), was synthesized by 157

Anaspec. All cathepsin-L assays were performed at room temperature in black, flat-bottom 384-well plates 158

containing a final reaction volume of 50 μL. Reactions were assembled as follows: 40 uL of 6.25 µg/mL human 159

CatL (Novoprotein) in Buffer A (50 mM ammonium acetate, pH 5.5, 0.1 mg/mL BSA, 4 mM EDTA, 2.5 mM 160 TCEP, 0.1% (v/v) Pluronic F-68) was dispensed into wells containing 0.1 µL of test compound in DMSO or 161 appropriate controls. The enzyme was incubated with the compounds for 10 min before substrate addition.

Reactions were initiated with 10 µL of 10 μM FRET peptide in Buffer A. Plates were shaken vigorously for 30 s, 163

and fluorescence generated by peptide cleavage was monitored continuously for 15 min on a Tecan Infinite 164 M200 Pro plate reader (λ excitation =485 nm; λ emission =535 nm). Slopes from the linear portions of each progress 165 curve were recorded and normalized to plate-based controls. Positive control wells, representing 100% 166 inhibition, excluded cathepsin-L enzyme; negative control wells, representing 0% inhibition, included vehicle. 167

HTS for inhibitors of CatL was performed using the primary assay, described above, against the TargetMol Recombinant SARS-CoV-2 Spike protein with C-terminal 6-His tag was purchased from R & D Systems, Inc. 500ng 191 of the spike protein was treated with 100ng recombinant human cathepsin-L (Sigma-Aldrich) in sodium acetate 192 buffer (pH 5.5) at room temperature for 4h in the presence of 2 and 20 µM concentrations of indicated inhibitors.

Cleavage of the spike protein was detected using anti-SARS-CoV Spike Protein (SDelta3) monoclonal antibody 194 (7G12, Thermo Fisher Scientific, CA, USA)) raised against immunogen aa168-461 of the S1 domain.

Pseudovirus entry inhibition assay 197 SARS CoV2 pseudotyped virus particles were produced by transfecting HEK293T cells with the following 198 plasmids 1) lentiviral backbone plasmid-pHAGE-CMV-Luc2-IRES-ZsGreen that expresses luciferase and 199

ZsGreen reporters. 

Inhibitory effect of selected compounds from 0.5 nM to 50 nM concentrations were determined using 3CL pro 229

and PL-Pro assay kits (BPS Bioscience, CA, USA) as per manufacturer's instructions. Briefly, indicated doses 230 of the compounds were pre-incubated with 150ng of 3CL-Pro or 15ng of PL-Pro for 30 min and then with 50µM 231 fluorogenic substrate either overnight at room temperature (for 3CL-Pro) or 1 hour at 37ºC (for PL-Pro). The 232

fluorescence at 460nM intensity was measured using a microplate reader. 233

Statistical analyses were performed using Prism GraphPad (V9.0). Data were expressed as Mean ± 235

SEM. Student's t-test was used to compare two groups, whereas ANOVA with Tukey's multiple comparisons 236 was used to compare more than two groups. A p-value < 0.05 was considered significant. 

We validated the use of hACE2 overexpressing 293T (hACE2-293T) cells for studying SARS CoV2 248 pseudovirus entry. We compared the specificity of SARS CoV2 spike-hACE2 mediated pseudovirus entry by 249

transducing wild type 293T vs hACE2-293T cells with VSV glycoprotein and SARS CoV2 spike glycoprotein 250

pseudotyped virus particles produced with luciferase reporter vector. As shown in Fig-1A -B, VSV-G 251 pseudotyped virus particles efficiently entered into both WT 293T and 293TACE2 cells, whereas SARS CoV2 252

pseudotyped virus particles entered only in hACE2-293T cells but not WT 293T cells. We performed an in vitro 253 S1/S2 cleavage assay in the presence of functional human CTSL enzyme and confirmed the ability of CTSL to 254

cleave SARS CoV2 spike (Fig-1C) . 255

To determine the relative importance of human CTSL and TMPRSS2 in mediating SARS Cov2 entry in 293T 256

ACE2 cells, we knocked out the expression of these genes by using the CRISPR-Cas9 method, and the 257 single-cell clones were expanded. The deletion of the targeted exon was confirmed by RT-PCR (Fig-S1 ). 258

Next, we determined the effect of the deletion of the CTSL and TMPRSS2 genes on SARS CoV2 virus entry 259 into 293T-ACE2 using the pseudovirus entry assay. Intriguingly, SARS CoV2 pseudotyped virus entry into 260 CTSL deleted 293T ACE2 cells was inhibited by ~70-80% relative to WT-293T ACE2 cells. On the other hand, 261

only ~20% of pseudovirus entry inhibition was noted in TMPRSS2 deleted 293T ACE2 cells suggesting a 262 dominant role of CTSL in mediating SARS CoV2 entry in 293T ACE2 cells compared to TMPRSS2 (Fig-1D) . 263

Next, we determined the susceptibility of WT, CTSL KO, and TMPRSS2 Ko 293T-ACE2 cells to SARS CoV2 264 infection. We monitored virus-induced cytopathic effect (CPE) using a luminescence-based cell viability assay 265

and found that CTSL deleted 293T-ACE2 cells were ~75% less susceptible to SARS CoV2 induced CPE 266 compared to WT cells, whereas there was no significant reduction in the CPE in TMPRSS2 KO cells (Fig-1E ). 267

Additionally, we determined the relative effect of these proteases using pharmacological inhibitors. As shown in 268 Fig-1F , cathepsin-L inhibitor effectively inhibited pseudovirus entry (>50%) at all doses tested ranging from 269

200nM to 5µM, whereas TMPRSS inhibitor did not show any inhibitory activity (Fig-1F) . 270

To identify inhibitors of cathepsin L-mediated cleavage of SARS-CoV2 Spike protein, we designed a FRET-272 based polypeptide containing the CTSL P5-P5' recognition sequence within the spike protein: (TAMRA)-273 IIAYT/MSLGAK-(FAM). Peptide hydrolysis by purified CTSL enzyme could be followed continuously by 274 measuring the appearance of FAM fluorescence over time, and hydrolysis could be inhibited by the addition of 275 previously characterized CTSL inhibitors, such as triapine (data not shown). This assay was used to screen 276 5,370 compounds in the TargetMol Bioactives library, a collection of heavily annotated small molecules, 277

including clinically-tested and FDA-approved compounds. The screen, performed using 20 uM test compound, 278

returned an average Z'-value of 0.74 and identified 112 compounds that reduced the slope of the CTSL-279 catalyzed reaction by 50% (Figure 2A ). Compounds that interfered with the assay signal or scored frequently in 280 screens of unrelated targets were removed from further consideration. The remaining 95 compounds were 281 triaged using a combination of factors, favoring: higher % CTSL inhibition; efficacy as anti-infective; activity as 282 protease inhibitor; chemical diversity; and including representative anti-inflammatory agents. 283

Bioactive libraries include many PAINS compounds (19) and although some were triaged because of assay 284

interference, hits such as the quinone visomitin, a redox-active PAINS compound, were also actively triaged.

Of the 27 hits selected, several could be considered as PAINS compounds because they contain an 286 electrophilic or redox-active functional group that interacts with the active site cysteine of cysteine proteases 287 and other enzymes: approximately 20 of the selected 27 hits have the potential for such interactions with the 288 active site cysteine of CTSL. For example, MG-132 is an aldehyde 20S proteasome inhibitor that also inhibits 289 calpains; boceprevir and telaprevir are ketoamide viral protease inhibitors; and GC-376 is a masked aldehyde 290 electrophile, requiring bio-activation to inhibit the 3CLpro main cysteine protease of SARS-CoV-2(20). 291

Next, 27 selected hits from our HTS CTSL cleavage assay were subjected to pseudovirus entry inhibition 294 assay using 293T-hACE2 cells. Among them, leupeptin hemisulfate, loxistatin acid, Z-FA-FMK, aloxistatin, ML-295 092, CCCP, MG-132, balicatib, FCCP, GC-376 sodium, AVN944, triapine, GlyH-101, and ML-364 exhibited 296

>50% pseudovirus entry inhibition in at least one of the tested doses i.e. 200nM, 1µM and 5µM (Fig-3A) . We 297 noted >50% cytotoxicity for compounds MG-132, AVN944, and triapine in 293T ACE2 cells (Fig-3B) , and 298 therefore, the observed reduction in RLUs in pseudovirus entry could be due to the cytotoxicity as well. 299

Next, we tested the ability of these drugs to inhibit SARS CoV2 infection and the associated cytopathic effect in 300

293T-hACE2 cells. Intriguingly, only three drugs namely, leupeptin hemisulfate, Z-FA-FMK, and GC-376 301 sodium effectively inhibited SARS CoV2 induced CPE in 293T ACE2 cells, whereas none of the other drugs 302

which inhibited pseudovirus entry in 293T ACE2 cells were capable of inhibiting cytopathic effect in 293T ACE2 303 cells (Fig-3C ). IC50 determination experiments showed an IC50 value of 0.64µM, 0.008 µM, and 0.02 µM for 304 leupeptin hemisulfate, Z-FA-FMK, and GC-376 respectively for inhibition of CPE in 293T ACE2 cells (Fig-3D) . 305

Next, we tested the effect of these drugs on CPE when added 1h post-infection (after virus absorption). All 306 three compounds had 25-20% reduction in their inhibitory effect when added post-infection (Fig-3E-F) , but 307

were still capable of producing more than 50% inhibitory effect on SARS CoV2 induced CPE. 308

susceptible cell lines with similar potency. 310

While 293T ACE2 cells are permissive to SARS CoV2 entry, the CPE was induced only at lower dilution (10 -2 ), 311

but increase in the number and size of plaques in cells expressing either TMPRSS2 or ACE2-TMPRSS2 324 compared to Vero E6 cells which were less susceptible to SARS CoV2 induced CPE (Fig-4B) . 325

Next, we examined the effect of the candidate drugs to inhibit SARS CoV2 infection in Vero TMPRSS2 and 326

Vero ACE2 TMPRSS2 cells. Compounds Z-FA-FMK and GC-376 inhibited SARS CoV2 CPE in Vero 327 TMPRSS2 cells under both pre and post-treatment conditions with similar efficacy. GC-376 had a better 328 inhibitory effect than Z-FA-FMK at 5µM dose (46.17±1.19 Vs 77.15±4.90). However, leupeptin hemisulfate 329 failed to show significant inhibition of SARS CoV2 induced CPE in these cells under both pre and post-330 treatment conditions (Fig-5A-B) . Both leupeptin hemisulfate and Z-FA-FMK were not effective in inhibiting 331 SARS CoV2 induced CPE in the Vero-ACE2-TMPRSS2 cell line (Fig-5C-D) . Only GC-376 inhibited SARS 332

CoV2 CPE in Vero-ACE2-TMPRSS2 cells at the highest 5µM concentration (Fig-5C-D) . 333

While these drugs can effectively inhibit host proteases for preventing SARS CoV2 entry their effect on virus 334

proteases such as 3CL pro and PLpro which are essential for virus replication couldn't be ruled out. Therefore, 335

we tested the efficacy of these compounds to inhibit 3CL-Pro and PL-Pro in vitro using fluorogenic substrate 336 cleavage assay and found that leupeptin had no significant inhibitory effect on either PL-pro or 3CL-Pro. GC-337 376 and Z-FA-FMK had IC50 values of 0.32µM and 9.67µM respectively against 3CL-Pro (Fig-5E ) they were 338

ineffective in inhibiting PL-Pro (data not shown). Thus, it is clear that the differences in the antiviral activity of 339 GC-376 vs Z-FA-FMK, although both could inhibit cathepsin-L with similar efficacy, could be attributed to the 340 higher efficiency of 3CL-Pro inhibition by GC-376 (Fig-2B) . Clinical trial results showed far from optimal activity of remdesivir in inhibiting SARS CoV2 replication (9) and 377 the reasoning for this suboptimal therapeutic efficacy of remdesivir could be that targeting RNA polymerase 378 alone may not be sufficient to clear or control viral load in many severe/hospitalized cases of COVID19. 379

Therefore, targeting additional key steps in SARS CoV2 infection such as virus entry could be critical. 380

Recently, the FDA has granted Emergency Use Authorizations (EUAs) for two drugs namely, molnupiravir and 381 nirmatrelvir/ritonavir for treating COVID19 patients which have shown better efficacy than Remdesivir (10).

Two host enzymes, TMPRSS2, and cathepsin-L, are known to be critical for mediating virus entry. Two major 383

virus proteases namely, 3-chymotrypsin-like proteases (3CL-Pro) and papain-like proteases (PL-Pro), are 384 necessary for the processing of several non-structural proteins (NSPs) needed for viral replication, and these 385 virus proteases are attractive targets for antiviral drugs (24, 25) . Here, we investigated the key factors 386

regulating SARS CoV2 entry such as cathepsin-L and TMPRSS2 using 293T cells overexpressing human 387 ACE2 (26). Several reports that emerged during the initial phase of the COVID19 pandemic emphasized 388 TMPRSS2 as the most important host factor mediating SARS CoV2 entry and indicated TMPRSS2 inhibition 389 as a therapeutic option for COVID19 (13, 27, 28) . Earlier, we had shown that the cathepsin-L cleavage site 390 was conserved in envelope proteins of different families of viruses such as SARS-CoV and Ebola, Hendra, and 391

Nipah viruses, and inhibition of cathepsin-L led to inhibition of entry of these viruses into host cells (18 overexpressing Vero cells and human lung Calu-3 cells (22) 376 against delta variant in different cell lines used in this study was comparable to their effects on the USA-455 WA1/2020 isolate and thus suggested that the observed mutations didn't affect the drug targets. Thus, we 456

report GC-376 can be a potential drug candidate for treating SARS CoV2 including the delta and omicron 457 variant. Given that the 3CL-Pro is targeted by the nirmatrelvir(39), it is possible that this drug can be effective 458

against the omicron variant as well but, yet to be proven. 459 GC-376 (a prodrug of GC-373) is structurally similar to nirmatrelvir (PF-07321332). Nirmatrelvir is an analog 460 with a substitution of aldehyde covalent cysteine (acceptor) with a nitrile. This drug is co-administered with low 461 dose ritonavir (used for blocking CYP3A4 to slow metabolism of nirmatrelvir) (39). The GC-376 and nimratrelvir 462 and their prodrugs are SARS-CoV-2 virus 3CL protease inhibitors. Core structures overlay very well and are 463 essential for 3CL-pro inhibition. Given that the 3CL-Pro is targeted by the nirmatrelvir, it is possible that this 464 drug can be effective against the omicron variant as well but, yet to be proven. Interestingly a recent study, 465

using the K18-hACE2 mouse model, has shown antiviral efficacy of GC-376 against SARS-CoV-2(40). GC-376 466 treatment was not toxic and improved survival from 0 to 20% in mice challenged with this virus. Treatment also 467 led to reduced viral loads and reduced inflammation in comparison to controls. This study with SARS-CoV2 468

further supports the notion that GC-376 is a promising lead candidate for further development. 469

Here, we report GC-376 can be a potential drug candidate for treating SARS CoV2 including the delta and 470 omicron variants. We furthermore report that GC-376 can inhibit SARS CoV2 infection by inhibiting more than 471 one proteolytic enzyme, thus limiting the ability of genetic variants to escape their anti-viral effect. Taken  472 together, our findings highlight the importance of targeting more than one aspect of the virus life cycle and 473

choosing a broad range of host cell lines for anti-viral drug screening. 

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected 511 Pneumonia

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Infection 519 and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Omicron-B.1.1.529 leads to widespread escape from 527 neutralizing antibody responses

Omicron 530 mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles

Efficacy of Antibodies and Antiviral Drugs 535 against Covid-19 Omicron Variant

Dual targeting of 3CL(pro) and PL(pro) of SARS-CoV-2: A novel 537 structure-based design approach to treat COVID-19

Structure of replicating SARS-CoV-2 539 polymerase

Remdesivir for the Treatment of Covid-19-Final Report

A tale of two antiviral targets -and the COVID-19 drugs that bind them

Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, 549 transmission, and vaccine resistance

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for 552 new drug development

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and 555 Is Blocked by a Clinically Proven Protease Inhibitor

Ready, Set, Fuse! The Coronavirus Spike Protein and Acquisition of Fusion 557 Competence

A genome-wide CRISPR screen identifies host factors 560 that regulate SARS-CoV-2 entry

Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of 28

Candidate drugs against SARS-CoV-2 and COVID-596 19

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-599 reactivity with SARS-CoV

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients

Covid-19-a double-blind randomized controlled trial. Eclinicalmedicine 35

Wild-type human coronaviruses prefer cell-surface TMPRSS2 to 607 endosomal cathepsins for cell entry

Clinical Isolates of Human Coronavirus 229E Bypass the 609 Endosome for Cell Entry

TMPRSS2 Contributes to

Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection

Inhibitors of cathepsin L 614 prevent severe acute respiratory syndrome coronavirus entry

Morphological cell profiling of 618 SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious 621 peritonitis

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the 634 treatment of COVID-19

Efficacy of GC-376 636 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model

293T WT and hACE2 overexpressing 293T (293T ACE2) cells were transduced with VSV-G 658 glycoprotein (A) and SARS CoV2 spike protein (B) pseudotyped virus particles and bar graphs show RLU 659 values for each cell type. C) Western blot shows cleavage of SARS CoV2 spike protein by CTSL enzyme

TMPRSS2 deleted 293T ACE2 cells were transduced with SARS CoV2 spike protein 661 pseudotyped virus particles and the bar graph shows relative pseudovirus entry inhibition compared to WT 662 293T ACE2 cells. E) Bar graph shows % inhibition of SARS CoV2 induced cytopathic effect

0001 Vs WT) F) Bar 664 graph shows % inhibition of SARS CoV2 pseudotyped virus entry in 293T-ACE2 cells exhibited by the 665 pharmacological inhibitors of CTSL and TMPRSS enzymes. (Assay was done in triplicates and two 666 independent experiments

A) A scatter plot of the inhibitory activity of each of the 5370 668 assayed compounds on CTSL activity with a FRET-based peptide representing a portion of the SARS CoV2 669 Spike protein. The grey section underlays the compounds that did not reach the cut-off criteria of 50% CTSL 670 inhibition. The compounds that progressed to validation in the pseudovirus entry assay are represented by red 671 circles. B) The structures of the top nine hits identified in the screen and prioritized for follow-up studies

Drug-induced cytotoxicity of the selected hits from the bioactive library in 293T ACE2 674 cells. C) Dose-response effect of selected hits from the bioactive library on SARS CoV2 induced cytopathic 675 effect in 293T ACE2 cells. D) CPE inhibition IC50 determination for leupeptin, Z-FA-FMK, and GC-376 sodium 676 in 293T ACE2 cells. E-F) Effect of the pre (E) and post-treatment (F) on SARS CoV2 induced CPE in 293T 677 ACE2 cells

Sensitivity of different cell lines to SARS CoV2 induced CPE as determined by CPE assays at 680 different dilutions. B) Vero E6, human TMPRSS2, and huACE2-TMPRSS2 overexpressing Vero E6 cells were 681 infected with indicated dilutions (10 -2 -10 -6 ) of SARS CoV2 isolate USA-WA1/2020, and plaques were 682 developed

on SARS CoV2 induced 684 CPE in (A) Vero-huTMPRSS2 (B) Vero-huACE2-huTMPRSS2 cells. C-D) Effect of post-treatment of leupeptin 685 hemisulfate, Z-FA-FMK, and GC-376 on SARS CoV2 induced CPE in (C) Vero-huTMPRSS2 and (D) Vero-686 huACE-huTMPRSS2 cells. E) IC50 determination for 3CL-Pro inhibitory activity of the compounds tested by in 687 vitro fluorogenic substrate cleavage assay

Mean ± SEM values from one independent experiment are shown)

Figure-6: A-B) Effect of post-treatment of leupeptin hemisulfate, Z-FA-FMK and GC-376 on SARS CoV2

.617.2 Delta Variant-induced CPE in (A) Vero-huTMPRSS2 (B) Vero-huACE2-huTMPRSS2 cells against 691

Delta Variant infection. C-D) Effect of post-treatment of leupeptin hemisulfate, Z-FA-692 FMK and GC-376 on SARS CoV2 B.1.1.529 omicron-induced CPE in (C) Vero-huTMPRSS2 (D) Vero-693 huACE2-huTMPRSS2 cells. (Assay was done in triplicates and 2-3 independent experiments